UPDATE : Thursday, December 12, 2019
294 shareholders file suit against Kolon TissueGene for damage compensation by Jeong Sae-im 2019-06-14 10:51
‘Many drugs won Chinese approval without review suspension’ by Jeong Sae-im 2019-06-13 11:26
Daewoong’s botulinum toxin hits a snag in European approval by Jeong Sae-im 2019-06-12 16:50
‘Medytox got review suspension in China only once’ by Jeong Sae-im 2019-06-11 10:50
CJ HealthCare to invest ₩100 billion in new IV fluid factory by Jeong Sae-im 2019-06-10 16:17
Medytox’ botulinum toxin may face approval delay in China by Jeong Sae-im 2019-06-10 13:55
Kolon TissueGene CEO resigns by Jeong Sae-im 2019-06-07 15:35
Pharma industry urges deregulation to develop new drug using AI by Jeong Sae-im 2019-06-05 11:53
FDA OKs phase-1 trial for Yuhan’s investigational lung cancer drug by Jeong Sae-im 2019-06-04 14:21
Kolon’s minority shareholders demand over ₩25 billion in damage by Jeong Sae-im 2019-06-03 14:53
Invossa inventor sold Kolon shares at highest value by Jeong Sae-im 2019-06-03 14:52
Hanmi’s hypertension drug was effective in phase-4 study  by Jeong Sae-im 2019-05-31 16:05
Until when will Kolon keep lying about Invossa? by Jeong Sae-im 2019-05-31 14:59
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug by Jeong Sae-im 2019-05-31 14:59
Announcement of Invossa license revocation was ‘procedural breach’: Kolon by Jeong Sae-im 2019-05-30 13:28
Medytox suspected of GMP violation filed at anti-corruption commission by Jeong Sae-im 2019-05-27 15:52
‘Shareholders can surely win lawsuit against Kolon’ by Jeong Sae-im 2019-05-24 19:34
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients by Jeong Sae-im 2019-05-22 11:59
Legislator, activists call for revoking Invossa license, conducting probes by Jeong Sae-im 2019-05-21 16:03
[Reporter’s Notebook] ‘Wanna know what’s going on with MSD Korea?’ by Jeong Sae-im 2019-05-21 11:44
Back to Top